KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Accounts Payables (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Accounts Payables for 18 consecutive years, with $26.0 million as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables rose 49.12% year-over-year to $26.0 million; the TTM value through Mar 2026 reached $26.0 million, up 49.12%, while the annual FY2025 figure was $28.1 million, 34.64% down from the prior year.
  • Accounts Payables hit $26.0 million in Q1 2026 for Ionis Pharmaceuticals, down from $28.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $43.0 million in Q4 2024 and bottomed at $5.6 million in Q3 2023.
  • Average Accounts Payables over 5 years is $18.5 million, with a median of $17.5 million recorded in 2025.
  • Year-over-year, Accounts Payables tumbled 72.67% in 2023 and then skyrocketed 146.67% in 2025.
  • Ionis Pharmaceuticals' Accounts Payables stood at $17.9 million in 2022, then soared by 45.23% to $26.0 million in 2023, then skyrocketed by 65.07% to $43.0 million in 2024, then tumbled by 34.64% to $28.1 million in 2025, then dropped by 7.31% to $26.0 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $26.0 million, $28.1 million, and $14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.